X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs LUPIN LTD - Comparison Results

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA LUPIN LTD SHASUN PHARMA/
LUPIN LTD
 
P/E (TTM) x 123.9 28.3 438.4% View Chart
P/BV x 8.5 3.0 288.6% View Chart
Dividend Yield % 0.2 0.6 41.5%  

Financials

 SHASUN PHARMA   LUPIN LTD
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
LUPIN LTD
Mar-18
SHASUN PHARMA/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs941,465 6.4%   
Low Rs46727 6.3%   
Sales per share (Unadj.) Rs214.2349.6 61.3%  
Earnings per share (Unadj.) Rs5.35.6 96.0%  
Cash flow per share (Unadj.) Rs15.829.6 53.5%  
Dividends per share (Unadj.) Rs1.005.00 20.0%  
Dividend yield (eoy) %1.40.5 313.6%  
Book value per share (Unadj.) Rs53.3300.3 17.8%  
Shares outstanding (eoy) m56.62452.08 12.5%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x0.33.1 10.4%   
Avg P/E ratio x13.1197.2 6.6%  
P/CF ratio (eoy) x4.437.1 11.9%  
Price / Book Value ratio x1.33.6 35.9%  
Dividend payout %18.790.0 20.8%   
Avg Mkt Cap Rs m3,958495,502 0.8%   
No. of employees `000NA17.0 0.0%   
Total wages/salary Rs m2,16428,647 7.6%   
Avg. sales/employee Rs ThNM9,273.6-  
Avg. wages/employee Rs ThNM1,681.0-  
Avg. net profit/employee Rs ThNM147.4-  
INCOME DATA
Net Sales Rs m12,127158,042 7.7%  
Other income Rs m2291,504 15.3%   
Total revenues Rs m12,356159,545 7.7%   
Gross profit Rs m1,00931,475 3.2%  
Depreciation Rs m59410,859 5.5%   
Interest Rs m4152,044 20.3%   
Profit before tax Rs m23020,076 1.1%   
Minority Interest Rs m0-71 0.0%   
Prior Period Items Rs m035 -0.9%   
Extraordinary Inc (Exp) Rs m0-14,644 0.0%   
Tax Rs m-732,885 -2.5%   
Profit after tax Rs m3022,513 12.0%  
Gross profit margin %8.319.9 41.8%  
Effective tax rate %-31.714.4 -220.3%   
Net profit margin %2.51.6 156.7%  
BALANCE SHEET DATA
Current assets Rs m6,884122,095 5.6%   
Current liabilities Rs m8,45650,956 16.6%   
Net working cap to sales %-13.045.0 -28.8%  
Current ratio x0.82.4 34.0%  
Inventory Days Days6285 72.9%  
Debtors Days Days108120 89.7%  
Net fixed assets Rs m4,970129,876 3.8%   
Share capital Rs m113904 12.5%   
"Free" reserves Rs m2,875134,866 2.1%   
Net worth Rs m3,020135,771 2.2%   
Long term debt Rs m1,81764,245 2.8%   
Total assets Rs m13,347263,054 5.1%  
Interest coverage x1.610.8 14.4%   
Debt to equity ratio x0.60.5 127.2%  
Sales to assets ratio x0.90.6 151.2%   
Return on assets %5.41.7 310.3%  
Return on equity %10.01.9 540.5%  
Return on capital %13.33.7 358.1%  
Exports to sales %46.40-   
Imports to sales %14.20-   
Exports (fob) Rs m5,622NA-   
Imports (cif) Rs m1,728NA-   
Fx inflow Rs m5,84353,141 11.0%   
Fx outflow Rs m2,17319,335 11.2%   
Net fx Rs m3,66933,807 10.9%   
CASH FLOW
From Operations Rs m39817,512 2.3%  
From Investments Rs m-1,635-14,073 11.6%  
From Financial Activity Rs m1,309-14,921 -8.8%  
Net Cashflow Rs m71-11,482 -0.6%  

Share Holding

Indian Promoters % 39.2 46.6 84.1%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 3.6 11.3 31.9%  
FIIs % 17.6 31.9 55.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 10.1 392.1%  
Shareholders   20,750 98,259 21.1%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   ORCHID PHARMA LTD  CIPLA  ABBOTT INDIA  UNICHEM LAB  WYETH LTD  

Compare SHASUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.

LUPIN LTD Announces Quarterly Results (1QFY19); Net Profit Up 21.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, LUPIN LTD has posted a net profit of Rs 4 bn (up 21.3% YoY). Sales on the other hand came in at Rs 26 bn (up 3.2% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA - SUVEN LIFE COMPARISON

COMPARE SHASUN PHARMA WITH

MARKET STATS